All In Biotech

Drug Trial Radar · NCT04786444

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-to-Lot Consistency of Three Lots of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Adults Aged 18 to 45 Years

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 409 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

409

Actual

Start

Feb 22, 2021

Primary completion

Jul 22, 2021

Study completion Jan 26, 2022

Sponsor

Lead sponsor
Valneva Austria GmbHIndustry
Sponsor type
Industry
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553 at the final dose. Overall 409 healthy subjects aged 18 to 45 years were randomized into the study.

Conditions

  • Chikungunya Virus Infection

Interventions

  • Biological Vaccine VLA1553Biological

    Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titer (GMT) of CHIKV-specific Neutralizing Antibodies as Determined by Microneutralization (μPRNT) Assay in Subjects Who Tested Negative for CHIKV Antibodies at BaselineTime frame: On Day 29 after single vaccination

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • AMR Miami

    Coral Gables, Florida

  • AMR Fort Myers

    Fort Myers, Florida

  • St. Johns Center for Clinical Research

    Ponte Vedra, Florida

  • AMR Wichita West

    Wichita, Kansas

  • AMR Lexington

    Lexington, Kentucky

  • Walter Reed Amy Institute of Research

    Silver Spring, Maryland

  • Alliance for Multispecialty Research (AMR)

    Kansas City, Missouri

  • Meridian Clinical Research

    Omaha, Nebraska

  • Wr-Crcn, Llc

    Las Vegas, Nevada

  • Rochester Clinical Research

    Rochester, New York

  • AMR Knoxville

    Knoxville, Tennessee

  • Dynamed Clinical Research

    Tomball, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.